Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Amortization of Deferred Charges (2020 - 2026)

Syndax Pharmaceuticals (SNDX) has disclosed Amortization of Deferred Charges for 6 consecutive years, with $56000.0 as the latest value for Q1 2026.

  • For Q1 2026, Amortization of Deferred Charges fell 50.0% year-over-year to $56000.0; the TTM value through Mar 2026 reached $172000.0, up 21.13%, while the annual FY2025 figure was $228000.0, 660.0% up from the prior year.
  • Amortization of Deferred Charges hit $56000.0 in Q1 2026 for Syndax Pharmaceuticals, up from -$1000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $792000.0 in Q3 2022 and bottomed at -$1.1 million in Q4 2022.
  • Average Amortization of Deferred Charges over 4 years is $31400.0, with a median of $59000.0 recorded in 2025.
  • Year-over-year, Amortization of Deferred Charges soared 538.71% in 2022 and then tumbled 103.33% in 2025.
  • Syndax Pharmaceuticals' Amortization of Deferred Charges stood at -$1.1 million in 2022, then soared by 102.72% to $30000.0 in 2024, then plummeted by 103.33% to -$1000.0 in 2025, then surged by 5700.0% to $56000.0 in 2026.
  • According to Business Quant data, Amortization of Deferred Charges over the past three periods came in at $56000.0, -$1000.0, and $62000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.